12 May 2026 : Original article
A Retrospective Study of 518 Kidney Transplant Recipients to Evaluate the Association of Antiplatelet Therapy With Long-Term Cardiovascular Events and All-Cause Mortality
Gavin Christy BCEF 1, Andres Mata ABE 2, Zalan Shah B 1, Ananta M.H. Sriram B 1, Diana Pfeiffer B 1, Taylor R. Coffman
B 1, Madeline K. Johnson E 1, Sahita Gandra E 1, Krista L. Lentine ADEG 3, Mina M. Benjamin ADE 4*
DOI: 10.12659/AOT.951325
Ann Transplant 2026; 31:e951325
Table 7 Adjusted Cox proportional hazards model for the endpoint of major adverse cardiovascular events in 518 kidney transplant recipients. The primary prevention subgroup included 368 patients without known cardiovascular disease.
| Variable | Study group | Primary prevention subgroup | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% confidence interval | P value | Hazard ratio | 95% confidence interval | P value | |
| Age | 1.03 | 1.01–1.04 | 1.02 | 1.00–1.05 | ||
| Antiplatelet therapy | 0.72 | 0.45–1.15 | 0.16 | 1.01 | 0.51–2.00 | 0.98 |
| Hemodialysis | 1.43 | 0.90–2.28 | 0.14 | – | – | – |
| Coronary artery disease | 1.82 | 1.14–2.93 | – | – | – | |
| Diabetes mellitus | 1.38 | 0.86–2.21 | 0.18 | – | – | – |
| Myocardial infarction | 0.71 | 0.30–1.69 | 0.43 | – | – | – |
| Cerebrovascular disease | 2.40 | 1.07–5.39 | – | – | – | |